Ocuphire Pharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4
- Today's High:
- $4.12
- Open Price:
- $4.08
- 52W Low:
- $1.9
- 52W High:
- $6.6
- Prev. Close:
- $4.05
- Volume:
- 248414
Company Statistics
- Market Cap.:
- $83.66 million
- Book Value:
- 1.797
- Revenue TTM:
- $45.27 million
- Operating Margin TTM:
- 40.1%
- Gross Profit TTM:
- $-14584000
- Profit Margin:
- 41.21%
- Return on Assets TTM:
- 36.98%
- Return on Equity TTM:
- 71.35%
Company Profile
Ocuphire Pharma Inc had its IPO on 2005-05-23 under the ticker symbol OCUP.
The company operates in the Healthcare sector and Biotechnology industry. Ocuphire Pharma Inc has a staff strength of 9 employees.
Stock update
Shares of Ocuphire Pharma Inc opened at $4.08 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4 - $4.12, and closed at $4.08.
This is a +0.74% increase from the previous day's closing price.
A total volume of 248,414 shares were traded at the close of the day’s session.
In the last one week, shares of Ocuphire Pharma Inc have increased by +4.08%.
Ocuphire Pharma Inc's Key Ratios
Ocuphire Pharma Inc has a market cap of $83.66 million, indicating a price to book ratio of 5.3958 and a price to sales ratio of 92.1672.
In the last 12-months Ocuphire Pharma Inc’s revenue was $45.27 million with a gross profit of $-14584000 and an EBITDA of $18.16 million. The EBITDA ratio measures Ocuphire Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ocuphire Pharma Inc’s operating margin was 40.1% while its return on assets stood at 36.98% with a return of equity of 71.35%.
In Q2, Ocuphire Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Ocuphire Pharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 4.1042
- PEG
Its diluted EPS in the last 12-months stands at $0.96 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ocuphire Pharma Inc’s profitability.
Ocuphire Pharma Inc stock is trading at a EV to sales ratio of 52.9728 and a EV to EBITDA ratio of -2.0097. Its price to sales ratio in the trailing 12-months stood at 92.1672.
Ocuphire Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $43.47 million
- Total Liabilities
- $5.76 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Ocuphire Pharma Inc ended 2024 with $43.47 million in total assets and $0 in total liabilities. Its intangible assets were valued at $43.47 million while shareholder equity stood at $37.70 million.
Ocuphire Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $5.76 million in other current liabilities, 2000.00 in common stock, $-82232000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $39.98 million and cash and short-term investments were $40.00 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Ocuphire Pharma Inc’s total current assets stands at $43.46 million while long-term investments were $0 and short-term investments were $22000.00. Its net receivables were $2.73 million compared to accounts payable of $2.32 million and inventory worth $687000.00.
In 2024, Ocuphire Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Ocuphire Pharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $4.08
- 52-Week High
- $6.6
- 52-Week Low
- $1.9
- Analyst Target Price
- $20.2
Ocuphire Pharma Inc stock is currently trading at $4.08 per share. It touched a 52-week high of $6.6 and a 52-week low of $6.6. Analysts tracking the stock have a 12-month average target price of $20.2.
Its 50-day moving average was $4.06 and 200-day moving average was $3.99 The short ratio stood at 15.6 indicating a short percent outstanding of 0%.
Around 413.1% of the company’s stock are held by insiders while 1892.4% are held by institutions.
Frequently Asked Questions About Ocuphire Pharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.